Published in J Cardiovasc Electrophysiol on March 28, 2007
Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ (2015) 1.65
Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol (2008) 0.97
Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period. Br J Clin Pharmacol (2008) 0.92
Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol (2015) 0.90
Relative contributions of TRIaD and QT to proarrhythmia. J Cardiovasc Electrophysiol (2007) 0.85
Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability. Br J Pharmacol (2008) 0.82
Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. BMJ (2016) 0.77
Arrhythmogenic actions of the Ca2+ channel agonist FPL-64716 in Langendorff-perfused murine hearts. Exp Physiol (2008) 0.75
Polymorphic ventricular tachycardia in acute myocardial infarction treated by thrombolysis: reperfusion, complication or iatrogenic sign? Maedica (Buchar) (2010) 0.75
[Ventricular tachyarrhythmia as a side effect of pharmacotherapy]. Herzschrittmacherther Elektrophysiol (2017) 0.75
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med (2015) 6.68
Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med (2007) 6.23
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 4.68
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet (2004) 3.88
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J (2004) 2.78
Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation (2004) 2.77
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation (2006) 2.76
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) (2004) 2.68
High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation (2006) 2.58
Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol (2002) 2.58
The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace (2009) 2.52
Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet (2002) 2.49
Occult atrial fibrillation in cryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiac monitors. Stroke (2013) 2.40
Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace (2012) 2.30
Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat (2003) 2.24
Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest (2013) 2.23
A survey of German centres performing invasive electrophysiology: structure, procedures, and training positions. Europace (2013) 2.19
Atrial fibrillation-induced cardiac troponin I release. Int J Cardiol (2013) 2.16
Pacemaker channel dysfunction in a patient with sinus node disease. J Clin Invest (2003) 2.14
The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J (2003) 2.10
Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J (2008) 2.09
Early outcomes for fenestrated and chimney endografts in the treatment of pararenal aortic pathologies are not significantly different: a systematic review with pooled data analysis. J Endovasc Ther (2012) 2.03
A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur Heart J (2006) 2.01
Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. Eur Heart J (2007) 1.98
Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol (2003) 1.98
Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. Heart Rhythm (2012) 1.91
Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol (2011) 1.91
Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res (2003) 1.91
Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J (2007) 1.90
Chronic kidney disease in patients with chronic heart failure--impact on intracardiac conduction, diastolic function and prognosis. Int J Cardiol (2006) 1.80
Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. J Cardiovasc Electrophysiol (2007) 1.79
Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation (2005) 1.78
Comparison of a novel, single-lead atrial sensing system with a dual-chamber implantable cardioverter-defibrillator system in patients without antibradycardia pacing indications: results of a randomized study. Circ Arrhythm Electrophysiol (2010) 1.72
Endovascular treatment of common iliac artery aneurysms using the bell-bottom technique: long-term results. J Endovasc Ther (2010) 1.69
Cardiac autonomic dysfunction in Brugada syndrome. Circulation (2002) 1.68
Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol (2011) 1.65
Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail (2008) 1.64
Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace (2013) 1.63
Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A(3) adenosine receptors. Cardiovasc Res (2004) 1.60
Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm (2010) 1.59
Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation. Eur Heart J (2007) 1.58
Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace (2011) 1.57
Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J (2008) 1.57
"Largest amplitude ablation" is the optimal approach for typical atrial flutter ablation: a subanalysis from the AURUM 8 study. J Cardiovasc Electrophysiol (2012) 1.56
Impact of sympathetic innervation on recurrent life-threatening arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging (2006) 1.55
Diastolic isthmus length and 'vertical' isthmus angulation identify patients with difficult catheter ablation of typical atrial flutter: a pre-procedural MRI study. Europace (2008) 1.54
Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure. Heart Rhythm (2011) 1.54
Gold vs. platinum-iridium tip catheter for cavotricuspid isthmus ablation: the AURUM 8 study. Europace (2010) 1.54
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Midterm results from the TRAVIATA registry: treatment of thoracic aortic disease with the valiant stent graft. J Endovasc Ther (2010) 1.51
Ablation of atrioventricular nodal reentrant tachycardia in the elderly: results from the German Ablation Registry. Heart Rhythm (2011) 1.51
Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol (2006) 1.51
Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm (2005) 1.50
Long-term support of 9 patients with the DeBakey VAD for more than 200 days. J Thorac Cardiovasc Surg (2005) 1.50
Isolated non-compaction cardiomyopathy. Dtsch Arztebl Int (2010) 1.49
Myocardial systolic and diastolic consequences of left ventricular mechanical dyssynchrony in heart failure with normal left ventricular ejection fraction. Eur Heart J Cardiovasc Imaging (2012) 1.49
Initial clinical experience with the HeartWare left ventricular assist system: a single-center report. Ann Thorac Surg (2012) 1.49
Molecular insights into arrhythmogenic right ventricular cardiomyopathy caused by plakophilin-2 missense mutations. Circ Cardiovasc Genet (2012) 1.48
Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: a long-term follow-up. Europace (2011) 1.47
Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens (2014) 1.46
Congenital heart defects in adulthood. Dtsch Arztebl Int (2011) 1.45
Spontaneous Brugada electrocardiogram patterns are rare in the German general population: results from the KORA study. Europace (2009) 1.45
Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): an on-treatment analysis. J Cardiovasc Electrophysiol (2013) 1.44
Self-rated health predicts adverse events during β-blocker treatment: the CIBIS-ELD randomised trial analysis. Int J Cardiol (2011) 1.44